MedTrace Logo

Optimization of Morphomer-based Alpha-synuclein PET Tracers

NCT05067192 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2021-10-05

No results posted yet for this study

Summary

The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow.

Promising PET-tracer candidates will be tested for their ability in detecting a-syn pathology in patients with a range of Parkinsonian conditions with different a-syn levels and distributions, comprising hereditary forms of PD and other synucleinopathies.

Conditions

Sponsors & Collaborators

  • AC Immune SA

    collaborator INDUSTRY

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Oskar Hansson, Professor · Skane University Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067192 on ClinicalTrials.gov